Efficacy and safety outcomes of the trials comparing NOACs with conventional therapy for acute VTE treatment
| . | Efficacy outcome . | Safety outcomes . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Recurrent VTE and VTE-related death . | Major bleeding . | Major and CRNB . | |||||||
| NOAC, n/N(%) . | Warfarin, n/N (%) . | ARR, % (95% CI) . | NOAC, n/N (%) . | Warfarin, n/N (%) . | ARR % (95% CI) . | NOAC n/N (%) . | Warfarin, n/N (%) . | ARR % (95% CI) . | |
| Dabigatran15 | 60/2553 (2.4) | 55/2554 (2.2) | 0.2 (−0.6, 1.0) | 37/2553 (1.4) | 51/2554 (2.0) | −0.5 (−1.3, 0.2) | 136/2553 (5.3) | 217/2554 (8.5) | −3.2 (−4.6, −1.8) |
| Rivaroxaban27 | 86/4130 (2.1) | 95/4131 (2.3) | −0.2 (−0.8, 0.4) | 40/4130 (1.0) | 72/4116 (1.7) | −0.8 (−1.3, −0.3) | 388/4130 (9.4) | 412/4116 (10.0) | −0.6 (−1.9, 0.7) |
| Apixaban18 | 59/2609 (2.3) | 71/2635 (2.7) | −0.4 (−1.3, 0.4) | 15/2676 (0.6) | 49/2689 (1.8) | −1.3 (−1.8, −0.6) | 115/2676 (4.3) | 261/2689 (9.7) | −5.4 (−6.8, −4.1) |
| Edoxaban19 | 130/4118 (3.2) | 146/4122 (3.5) | −0.4 (−1.2, 0.4) | 56/4118 (1.4) | 66/4122 (1.6) | −0.2 (−0.8, 0.3) | 349/4118 (8.5) | 423/4112 (10.3) | −1.8 (−3.1, −0.6) |
| . | Efficacy outcome . | Safety outcomes . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Recurrent VTE and VTE-related death . | Major bleeding . | Major and CRNB . | |||||||
| NOAC, n/N(%) . | Warfarin, n/N (%) . | ARR, % (95% CI) . | NOAC, n/N (%) . | Warfarin, n/N (%) . | ARR % (95% CI) . | NOAC n/N (%) . | Warfarin, n/N (%) . | ARR % (95% CI) . | |
| Dabigatran15 | 60/2553 (2.4) | 55/2554 (2.2) | 0.2 (−0.6, 1.0) | 37/2553 (1.4) | 51/2554 (2.0) | −0.5 (−1.3, 0.2) | 136/2553 (5.3) | 217/2554 (8.5) | −3.2 (−4.6, −1.8) |
| Rivaroxaban27 | 86/4130 (2.1) | 95/4131 (2.3) | −0.2 (−0.8, 0.4) | 40/4130 (1.0) | 72/4116 (1.7) | −0.8 (−1.3, −0.3) | 388/4130 (9.4) | 412/4116 (10.0) | −0.6 (−1.9, 0.7) |
| Apixaban18 | 59/2609 (2.3) | 71/2635 (2.7) | −0.4 (−1.3, 0.4) | 15/2676 (0.6) | 49/2689 (1.8) | −1.3 (−1.8, −0.6) | 115/2676 (4.3) | 261/2689 (9.7) | −5.4 (−6.8, −4.1) |
| Edoxaban19 | 130/4118 (3.2) | 146/4122 (3.5) | −0.4 (−1.2, 0.4) | 56/4118 (1.4) | 66/4122 (1.6) | −0.2 (−0.8, 0.3) | 349/4118 (8.5) | 423/4112 (10.3) | −1.8 (−3.1, −0.6) |
ARR, absolute risk reduction; CRNB, clinically relevant nonmajor bleeding; n/N (%), number of events/number of patients in group (percentage).